ATE409188T1 - Naphthyridinverbindungen - Google Patents

Naphthyridinverbindungen

Info

Publication number
ATE409188T1
ATE409188T1 AT06773519T AT06773519T ATE409188T1 AT E409188 T1 ATE409188 T1 AT E409188T1 AT 06773519 T AT06773519 T AT 06773519T AT 06773519 T AT06773519 T AT 06773519T AT E409188 T1 ATE409188 T1 AT E409188T1
Authority
AT
Austria
Prior art keywords
sub
naphthyridine compounds
histamine
receptor
serotonin
Prior art date
Application number
AT06773519T
Other languages
English (en)
Inventor
Michael LETAVIC
John Keith
Nicholas Carruthers
Chandravadan Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE409188T1 publication Critical patent/ATE409188T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06773519T 2005-06-17 2006-06-16 Naphthyridinverbindungen ATE409188T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69200305P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ATE409188T1 true ATE409188T1 (de) 2008-10-15

Family

ID=37263777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06773519T ATE409188T1 (de) 2005-06-17 2006-06-16 Naphthyridinverbindungen

Country Status (14)

Country Link
US (1) US7417054B2 (de)
EP (1) EP1899334B1 (de)
JP (1) JP2008543880A (de)
CN (1) CN101243083A (de)
AT (1) ATE409188T1 (de)
AU (1) AU2006261162A1 (de)
CA (1) CA2612409A1 (de)
DE (1) DE602006002894D1 (de)
DK (1) DK1899334T3 (de)
ES (1) ES2314933T3 (de)
PL (1) PL1899334T3 (de)
PT (1) PT1899334E (de)
SI (1) SI1899334T1 (de)
WO (1) WO2006138714A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
AU2004283196B2 (en) * 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
CN101243082A (zh) * 2005-06-17 2008-08-13 詹森药业有限公司 治疗cns障碍的六氢-吡咯并-异喹啉化合物
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2656075A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
CN101511790A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 取代的氨基甲基苯甲酰胺化合物
CA2656089A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008064036A1 (en) * 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators
US20090099158A1 (en) * 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
JP2011518127A (ja) * 2008-03-31 2011-06-23 エヴォテック・アクチエンゲゼルシャフト ヒスタミンh3受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
JP5364327B2 (ja) * 2008-09-26 2013-12-11 富士フイルム株式会社 ハロピラジンカルボキサミド化合物の製造方法
CN113024456B (zh) * 2021-02-23 2022-05-13 江苏先导药业有限公司 一种2-氯烟酸的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH538477A (de) 1970-01-06 1973-06-30 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
GB1558043A (en) * 1976-02-03 1979-12-19 Onoda Cement Co Ltd Metal squeeze out tube and method and apparatus for forming a powder layer on its surface
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
EP0978512A1 (de) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Aryloxy- (oder Arylthio)alkylamine ohne Imidazolring als Histamin-H3-Antagonisten und deren therapeutische Anwendung
KR100878855B1 (ko) 1999-11-03 2009-01-15 에이엠알 테크놀로지, 인크. 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과 도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도
EP1113007A1 (de) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
EP1595881A1 (de) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
DE602005026169D1 (de) 2004-12-17 2011-03-10 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen

Also Published As

Publication number Publication date
WO2006138714A2 (en) 2006-12-28
WO2006138714A3 (en) 2007-03-15
US20060287292A1 (en) 2006-12-21
EP1899334B1 (de) 2008-09-24
DE602006002894D1 (de) 2008-11-06
SI1899334T1 (sl) 2009-04-30
DK1899334T3 (da) 2008-11-24
US7417054B2 (en) 2008-08-26
CA2612409A1 (en) 2006-12-28
PL1899334T3 (pl) 2009-04-30
JP2008543880A (ja) 2008-12-04
EP1899334A2 (de) 2008-03-19
CN101243083A (zh) 2008-08-13
ES2314933T3 (es) 2009-03-16
PT1899334E (pt) 2008-11-06
AU2006261162A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
ATE409188T1 (de) Naphthyridinverbindungen
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
HK1118550A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE539753T1 (de) Pyrimidin-verbindungen als serotonin-rezeptor- modulatoren
WO2008002820A3 (en) Substituted benzyl amine compounds
ATE461217T1 (de) Glp-1-verbindungen
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
AT9566U3 (de) Kopierfräseinrichtung zur herstellung von zahntechnischen werkstücken
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
MY145305A (en) Cyclopropyl amines as modulators of the histamine h3 receptor
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
SE0301650D0 (sv) Novel compounds
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
UA85563C2 (ru) Конденсированные гетероциклические соединения
GB0515025D0 (en) Organic compounds
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899334

Country of ref document: EP

REN Ceased due to non-payment of the annual fee